NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial -

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Liver disorders
Summary
At 12 weeks, 20 (74%) of 27 patients who received 3 mg NGM282 and 22 (79%) of 28 patients who received 6 mg NGM282 met the primary endpoint of a 5% or more decrease in absolute liver fat content, compared with two (7%) of 27 patients in the placebo group.
UKMi comment

This study assessed the safety and efficacy of NGM282, an engineered FGF19 analogue, for the treatment of non-alcoholic steatohepatitis.

In a related editorial, the authors comment that studies of much longer duration that show a clinically relevant sustained benefit of treatment (transaminase concentrations returned toward baseline 4 weeks after cessation of treatment with NGM282), net of adverse events, are needed.
Related links: Comment